Riluzole

Sodium channel protein inhibitor CAS# 1744-22-5

Riluzole

Catalog No. BCC3849----Order now to get a substantial discount!

Product Name & Size Price Stock
Riluzole:100mg $58.00 In stock
Riluzole:200mg $99.00 In stock
Riluzole:500mg $232.00 In stock
Riluzole:1000mg $406.00 In stock
Related Products

Quality Control of Riluzole

Number of papers citing our products

Chemical structure

Riluzole

3D structure

Chemical Properties of Riluzole

Cas No. 1744-22-5 SDF Download SDF
PubChem ID 5070 Appearance Powder
Formula C8H5F3N2OS M.Wt 234.2
Type of Compound N/A Storage Desiccate at -20°C
Synonyms PK 26124
Solubility Soluble in DMSO > 10 mM
Chemical Name 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
SMILES C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
Standard InChIKey FTALBRSUTCGOEG-UHFFFAOYSA-N
Standard InChI InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Riluzole

DescriptionRiluzole is an anticonvulsant drug and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.In Vitro:Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM. At 20 μM, Riluzole inhibits peak autaptic IPSCs only slightly but prolongs IPSCs reliably. It is also found that Riluzole causes a strong, concentration-dependent, readily reversible enhancement of responses to 2 μM GABA. At higher concentrations of Riluzole, especially 300 μM, GABA currents exhibit apparent desensitization during prolonged co-exposure to 2 μM GABA and Riluzole. The EC50 of Riluzole potentiation of GABA responses is about 60 μM[1].In Vivo:In normal naïve rats, systemic injection of Riluzole (8 mg/kg, i.p.; n=6 rats) decreases the duration of ultrasonic but not audible vocalizations evoked by noxious stimulation of the knee joint compare to vehicle tested in the same rats (P<0.05). Systemic application of Riluzole (8 mg/kg, i.p.; n=19 rats) decreases the vocalizations of arthritic rats compare to predrug and vehicle significantly (P<0.05 to 0.001). Riluzole administered into the CeA significantly decreases the duration of audible and ultrasonic vocalizations evoked by noxious stimulation of the knee compare to predrug values (n=8 rats; P<0.05 to 0.01)[2].

References:
[1]. He Y, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002 Feb;42(2):199-209. [2]. Thompson JM, et al. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Mol Pain. 2015 Aug 28;11:51.

Protocol

Cell Assay [1]
Two-electrode voltage clamp of Xenopus oocytes expressing exogenous GABAA receptors is performed with a CA-1B high performance oocyte clamp. The extracellular recording solution is ND-96 medium. Riluzole is applied from a common tip via a gravity-driven multibarrel drug-delivery system. Data acquisition and analysis are performed with pCLAMP 6 software[1].

Animal Administration [2]
Adult male Sprague-Dawley rats (180 to 350 g) are housed in a temperature-controlled room and maintained on a 12-h day/night cycle with unrestricted access to food and water. Pain behaviors are measured before and 5 h after induction of a mono-arthritis in the left knee joint. To test the effects of systemic (intraperitoneal, i.p.) application of Riluzole, pain behaviors are measured 1 h postinjection of Riluzole in normal and arthritic animals. To determine effects of Riluzole into the amygdala, pain behaviors are measured 15 min after starting Riluzole application through a stereotaxically implanted microdialysis probe. To investigate site of action in the amygdala of systemically applied Riluzole, potassium channel blockers are administered into the amygdala 45 min after systemic application of Riluzole and pain behaviors are measured 15 min later, i.e., 1 h postinjection of riluzole (i.p.)[2].

References:
[1]. He Y, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002 Feb;42(2):199-209. [2]. Thompson JM, et al. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Mol Pain. 2015 Aug 28;11:51.

Riluzole Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Riluzole Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Riluzole

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.2699 mL 21.3493 mL 42.6985 mL 85.3971 mL 106.7464 mL
5 mM 0.854 mL 4.2699 mL 8.5397 mL 17.0794 mL 21.3493 mL
10 mM 0.427 mL 2.1349 mL 4.2699 mL 8.5397 mL 10.6746 mL
50 mM 0.0854 mL 0.427 mL 0.854 mL 1.7079 mL 2.1349 mL
100 mM 0.0427 mL 0.2135 mL 0.427 mL 0.854 mL 1.0675 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Riluzole

Riluzole, a novel glutamate-modulating agent, has neuroprotective effects [1] [2], via a complex mechanism involving inhibition of voltage-dependent Na channels, high-voltage activated Ca and K channels, and inhibition of protein kinase C. It was suggested that this mechanism was involved in antioxidative processes [3]. The IC50 to inhibit inward Na+ currents in primary cultures of rat cortical neurons is 51 μM [4].
Glutamate-mediated impairments were related to neurodegenerative diseases. Reduction of excess central nervous system (CNS) glutamate was the same aim of several treatment strategies [1] [5].
In HEKGLT1, HEKGLAST or HEKEAAC1 cells, riluzole increased Na+-dependent uptake in a dose-dependent manner, with significant effects at concentrations as low as 0.01–0.1 μM and the highest effect at 100 μM. The increase in glutamate uptake induced by 100 μM riluzole was similar in all cell lines (+27% in HEKGLAST, +38% in HEKGLT1, +39% in HEKEAAC1). Higher riluzole concentrations (300 and 1000 μM) were toxic, since at the end of experiments the majority of cells were floating, and specific and non-specific glutamate uptake were reduced by more than 50% [3].
In rat cortical synaptosomes, Na+-dependent L-[3H] glutamate uptake was increased by riluzole (0.1-100μM), a significant 16% increase was found with 100μM riluzole. With 300μM riluzole, no real effect was found on glutamate uptake. Possibly high concentration can lead to toxic effects. Both specific and non-specific glutamate uptakes were markedly reduced (about 50%) by 1 mM riluzole, at this concentration, synaptosomal integrity may be lost [3].
References:
[1]. Christiane Malgouris, Florence Bardot, Marc Daniel, et al. Riluzole, a Novel Antiglutamate, Prevents Memory Loss Hippocampal Neuronal Damage in lschemic Gerbils. The Journal of Neuroscience, 1989, 9(11): 3720-3727.
[2]. Carlos A. Zarate, Jr., Jennifer L. Payne, Jorge Quiroz, et al. An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression. Am J Psychiatry, 2004, 161:171-174.
[3]. Elena Fumagalli, Marcella Funicello, Thomas Rauen, et al. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. European Journal of Pharmacology, 2008, 578: 171-176.
[4]. Masanori Ohashi, Akiyoshi Saitoh, Misa Yamada, et al. Riluzole in the prelimbic medial prefrontal cortex attenuates veratrine-induced anxiety-like behaviors in mice. Psychopharmacology, 2015, 232:391–398.
[5]. M. J. Hudspith. Glutamate: a role in normal brain function, anaesthesia, analgesia and CNS injury. British Journal of Anaesthesia, 1997, 78: 731-747.

Featured Products
New Products
 

References on Riluzole

Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.[Pubmed:28231291]

PLoS One. 2017 Feb 23;12(2):e0171256.

Osteosarcomas are malignant tumors of bone, most commonly seen in children and adolescents. Despite advances in modern medicine, the poor survival rate of metastatic osteosarcoma has not improved in two decades. In the present study we have investigated the effect of Riluzole on a human and mouse metastatic osteosarcoma cells. We show that LM7 cells secrete glutamate in the media and that mGluR5 receptors are required for the proliferation of LM7 cells. Riluzole, which is known to inhibit glutamate release, inhibits proliferation, induces apoptosis and prevents migration of LM7 cells. This is also seen with Fenobam, a specific blocker of mGluR5. We also show that Riluzole alters the phosphorylation status of AKT/P70 S6 kinase, ERK1/2 and JNK1/2. Thus Riluzole is an effective drug to inhibit proliferation and survival of osteosarcoma cells and has therapeutic potential for the treatment of osteosarcoma exhibiting autocrine glutamate signaling.

Administration of riluzole into the basolateral amygdala has an anxiolytic-like effect and enhances recognition memory in the rat.[Pubmed:28359884]

Behav Brain Res. 2017 Jun 1;327:98-102.

It is widely thought that inactivation of the glutamatergic system impairs recognition memory in rodents. However, we previously demonstrated that systemic administration of Riluzole, which blocks the glutamatergic system, enhances recognition memory in the rat novel object recognition (NOR) test. The mechanisms underlying this paradoxical effect of Riluzole on recognition memory remain unclear. In the present study, adult male Wistar rats were bilaterally cannulated in the basolateral amygdala (BLA) to examine the effects of intra-BLA administration of Riluzole. We also compared the effects of Riluzole with those of d-cycloserine, a partial agonist at the glycine binding site on the N-methyl-d-aspartate (NMDA) receptor. The BLA plays a critical role not only in recognition memory, but also in the regulation of anxiety. In the present study, intra-BLA administration of Riluzole or d-cycloserine enhanced recognition memory in the NOR test. It was previously suggested that recognition memory can be strongly affected by the state of anxiety in rodents. Interestingly, intra-BLA administration of Riluzole, but not d-cycloserine, produced a potent anxiolytic-like effect in the elevated plus-maze test. Thus, the enhancement of recognition memory by Riluzole might be an indirect effect resulting from the anxiolytic-like action of the intra-BLA administration of the drug, and may not be directly related to inhibition of the glutamatergic system. Further studies are needed to clarify the mechanisms underlying the memory enhancing effect of Riluzole.

A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression.[Pubmed:28338546]

J Clin Psychopharmacol. 2017 Jun;37(3):355-358.

BACKGROUND: Glutamatergic system abnormalities are implicated in the pathophysiology and treatment of both major depressive disorder and bipolar depression (BDep). Subsequent to studies demonstrating the rapid and robust antidepressant effects of ketamine, an N-methyl-D-aspartate receptor antagonist, other glutamatergic modulators are now being studied in clinical trials of mood disorders. A previous open-label study found that Riluzole, administered in combination with the mood stabilizer lithium, had antidepressant effects. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of Riluzole monotherapy for the treatment of BDep. Nineteen subjects aged 18 to 70 years with bipolar disorder currently experiencing a depressive episode were tapered off of excluded medications and randomized to receive Riluzole (50-200 mg/d) or placebo for 8 weeks. Rating scale scores (Montgomery-Asberg Depression Rating Scale, Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, and Young Mania Rating Scale) were obtained weekly. RESULTS: No significant differences in depressive symptoms were observed between subjects treated with Riluzole and those receiving placebo (P = 0.12). Anxiety scores were significantly lower in the placebo group (P = 0.046). An interim analysis was conducted that resulted in stopping the study because of futility; no subjects had achieved treatment response. CONCLUSIONS: Although we found no change in severity of depressive symptoms in BDep patients receiving Riluzole compared with placebo, this trial was limited by the relatively high number of subject withdrawals and the small sample size. Thus, while Riluzole monotherapy did not demonstrate efficacy for BDep, further studies examining Riluzole as adjunctive therapy for this disorder may be warranted.Clinical Trials Identifier NCT00054704.

Description

Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.

Keywords:

Riluzole,1744-22-5,PK 26124,Natural Products,Sodium Channel, buy Riluzole , Riluzole supplier , purchase Riluzole , Riluzole cost , Riluzole manufacturer , order Riluzole , high purity Riluzole

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: